Crinetics Pharmaceuticals Awarded $1.5MM NIH Phase II SBIR Grant for PCOS Research

Crinetics Pharmaceuticals receives a $1.5MM Phase II SBIR grant to develop orally-available, small molecule kisspeptin receptor antagonists to treat polycystic ovary syndrome (PCOS) and other women’s health disorders.

This program represents a significant extension of Crinetics’ efforts to develop drugs that target endocrine diseases and endocrine related cancers. With this program our goal is to give physicians an important new tool to help the millions of women suffering with PCOS,” said Scott Struthers Ph.D., Founder and CEO of Crinetics.

Dr. Struthers is a strong supporter of San Diego entrepreneurs through his position as President of the SDEE Executive Committee.

Visit to learn more about our exciting research!